Overview

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Status:
Not yet recruiting

Trial end date:
2024-11-14

Target enrollment:

Participant gender:

Summary

This multicenter randomized, open-label study aime to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or chronic pediatric ITP patients who had not responded to or had relapsed after previous hormone treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Collaborators:

Beijing Children's Hospital
Henan Cancer Hospital
The First Affiliated Hospital of Xiamen University
The Second Affiliated Hospital of Kunming Medical University
Tianjin Medical University Second Hospital
Tianjin People's Hospital

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins